Omada Health vs. Establishment Labs: Investment Showdown

Investors are increasingly weighing the merits of two distinct medical companies, Omada Health and Establishment Labs, as potential investment opportunities. Both companies operate within the healthcare sector but focus on different markets and services. This article provides a comparative analysis based on several key factors, including institutional ownership, valuation, analyst recommendations, profitability, earnings, dividends, and risk.

Valuation and Earnings

Omada Health, trading under the ticker NASDAQ:OMDA, has demonstrated strong revenue growth. The company’s revenue surged from $122.8 million in 2023 to $169.8 million in 2024, reflecting a 38% year-over-year increase. In the first quarter of 2025, Omada reported revenues of $55.0 million, up by 57% from $35.1 million in the same period of 2024.

In contrast, Establishment Labs, listed as NASDAQ:ESTA, specializes in medical devices for aesthetic and reconstructive surgery, particularly silicone gel-filled breast implants. While specific revenue figures for Establishment Labs were not disclosed in this analysis, the company has shown a steady presence in international markets, selling products across Europe, the Middle East, Latin America, and Asia.

Profitability and Analyst Recommendations

Profitability metrics further distinguish these two companies. Omada Health’s net margins, return on equity, and return on assets indicate a robust financial outlook, although it has yet to achieve annual profitability due to significant investments in program development. Insiders hold 11.1% of Establishment Labs shares, while institutional investors own 72.9%, suggesting confidence in its long-term growth potential.

Analysts currently favor Omada Health with a consensus price target of $27.11, implying a potential upside of 71.81%. Establishment Labs, on the other hand, has a lower consensus price target of $78.86, indicating a modest potential upside of 8.20%. This data, reported by MarketBeat, suggests that analysts view Omada Health as a more favorable investment option at present.

Omada Health’s mission centers on improving chronic disease management, a significant concern in the United States, where over 156 million Americans are affected by one or more chronic conditions. The company aims to empower individuals to make lasting health changes through its virtual care programs, which have engaged over 679,000 members since their inception in 2012.

Establishment Labs, founded in 2004 and headquartered in Alajuela, Costa Rica, focuses on providing innovative medical devices for plastic surgery. It has established a strong market presence, but its financial performance and growth trajectory remain less pronounced than that of Omada Health.

In conclusion, a comparison of these two companies reveals that Omada Health outperforms Establishment Labs in six out of nine key investment metrics. As the healthcare landscape continues to evolve, investors may want to consider these factors when determining their next investment move.